Sten Verland - Orphazyme Director
| ORPHA Stock | DKK 924.50 9.50 1.04% |
Director
Dr. Sten Verland, Ph.D. serves as Director of Orphazyme AS. He is Partner and cofounder at Sunstone Capital AS. He serves on the BoD of Orphazyme ApS, Zymenex AS, Action Pharma AS, F2G Ltd., Scanbur AS, StemCare AS, and Vaximm AG. He is serial biotech entrepreneur. He was involved in the startup and management of several companies including Synarc Inc., MB AS, and StemCare AS. He previously was VP General Manager Europe at Synarc, Inc. CEO and coowner at MB AS. He is postdoctoral fellow and Ph.D. in Immunology at the University of Copenhagen.
| Professional Marks | Ph.D |
| Phone | 45 39 17 82 72 |
| Web | https://www.orphazyme.com |
Orphazyme Management Efficiency
The company has return on total asset (ROA) of (1.334) % which means that it has lost $1.334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.8658) %, meaning that it generated substantial loss on money invested by shareholders. Orphazyme's management efficiency ratios could be used to measure how well Orphazyme manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 |
Orphazyme AS Leadership Team
Elected by the shareholders, the Orphazyme's board of directors comprises two types of representatives: Orphazyme inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orphazyme. The board's role is to monitor Orphazyme's management team and ensure that shareholders' interests are well served. Orphazyme's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orphazyme's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Remi Droller, Director | ||
| Anders Hedegaard, Director | ||
| MBA MSc, CFO CEO | ||
| Georges Gemayel, Chairman of the Board | ||
| Jennifer McCann, I US | ||
| Bo Hansen, Deputy Chairman of the Board | ||
| Anders Vadsholt, Interim Chief Executive Officer, Chief Financial Officer | ||
| Thomas Blaettler, Chief Medical Officer | ||
| Catherine Moukheibir, Director | ||
| Sten Verland, Director | ||
| Kim Stratton, Chief Executive Officer | ||
| Martin Bonde, Director | ||
| Thomas Jensen, Chief Scientific Officer | ||
| Martijn Kleijwegt, Director |
Orphazyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orphazyme a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 | |||
| Profit Margin | (2.76) % | |||
| Operating Margin | (15.38) % | |||
| Current Valuation | (12.81 M) | |||
| Shares Outstanding | 35.31 M | |||
| Shares Owned By Insiders | 1.36 % | |||
| Shares Owned By Institutions | 8.13 % | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.05 X |
Pair Trading with Orphazyme
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orphazyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orphazyme will appreciate offsetting losses from the drop in the long position's value.Moving together with Orphazyme Stock
Moving against Orphazyme Stock
The ability to find closely correlated positions to Orphazyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orphazyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orphazyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orphazyme AS to buy it.
The correlation of Orphazyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orphazyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orphazyme AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orphazyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Orphazyme Stock
Orphazyme financial ratios help investors to determine whether Orphazyme Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orphazyme with respect to the benefits of owning Orphazyme security.